In the present study, whole exome sequencing detected a novel heterozygous nonsense variant c.1063G > T (p.E355X) in the ASXL3 gene (NM_030632.3) in a Chinese girl with BRPS. Sanger sequencing confirmed the wildtype in parents and fetal which revealed the dominant de novo pattern. In silico prediction analysis demonstrated this variant had damaging or disease-causing effects (PVS1 + PM1 + PM2) according to ACMG guidelines [21]. ASXL3 c.1063G > T (p.E355X), locating in mutation cluster region (MCR) in exon 11, is a nonsense variant which causes the truncating of the protein. The proband presented in this study exhibit most of the typical clinical manifestations of BRPS including feeding difficulties, hypotonia, absent speech, intellectual disability and facial dysmorphism. Our study reports a novel variant in ASXL3 which enriches the genetic spectrum and further emphasizes the dominant inheritance of BRPS.
BRPS was first described in 2013, in four patients with ASXL3 de novo mutations. To date, 54 patients with a wide age range from 4 months to 47 years were reported [1, 2, 5, 11–20, 22–30]. Mutation spectrum of ASXL3 and the number of patients were listed in Table 1. Forty-five different pathogenic mutations in ASXL3 were summarized with 22 patients in exon 11 and 32 patients in exon 12. All the described mutations are nonsense or frameshift variants except one splice site mutation carried by two separate patients. In addition to the spice site mutation, variant c.3106C > T (p.Arg1036*) was detected in five patients and c.4330C > T (p.Arg1444*) was detected in three patients, which suggested they are likely mutational hotspots. The prediction that phenotype severity decreases as the variants occur further away from the 5’-end of exon 11 and towards the 3’-end needs to be further confirmed[19]. More patients should be collected to study the genotype-phenotype correlation in this severe atypical neurodevelopmental disorder.
In our study, the proband was diagnosed as BRPS and the parents were phenotypic and genetic normal. Considering the recurrence risk, the pregnant mother still had prenatal diagnosis and the negative result excluded the gonadal mosaicism of the couple. The prenatal diagnosis of BRPS was challenging owing to its limited ultrasonography findings. Polyhydramonios, decreased fetal movements in late pregnancy and anthrogryposis on ultrasound were observed on separate fetus [5, 11, 20, 29]. In our study, reduced fetal movement was found during pregnancy and bilateral varus deformity of feet was observed at birth, which were consistent with the reported fetal cases. The limited prenatal cases revealed that reduced fetal movements and anthrogryposis on ultrasound maybe the clinical features of the BRPS fetus. Prenatal imaging results combining with molecular genetic analysis would help a clear diagnosis. In previous studies, three families had sibling recurrent variants and one family had mosaicism variant in the proband. Germline mosaicism in one of the parents seems to be a more likely explanation [20, 23]. Within the families, behavioral phenotype diversity and difference in intellectual development among siblings with consistent variants have demonstrated the heterogeneity of this clinical condition [20]. A nonsense ASXL3 mutation carried by a patient with developmental delay and hypotonia was inherited from the clinically unaffected father, which suggests incomplete penetrance [13, 31]. Accurate genetic counselling should be carefully performed in families of a child with a dominant genetic condition caused by a de novo pathogenic variant.
De novo truncating ASXL3 mutations are predicted to promote nonsense-mediated decay (NMD) and disrupt the normal activity of the Polycomb repressive deubiquitination (PR-DUB) complex. Transcriptome analysis of ASXL3 fibroblasts from patients with BRPS resulting the differentially expressed genes (DEGs) have suggested that ASXL3 is involved in transcriptional regulation of brain development genes [11]. Besides a causing dominant gene responsible for BRPS phenotype, compound heterozygous variants in ASXL3 have also been proposed to cause congenital heart disease (CHD) and recurrent mutations in ASXL3 have been identified in specific subset of cancer [7–9]. Potentially, the underlying mechanism may be that different kinds of variants in ASXL3 cause various mRNA expression and protein levels across clinical conditions. Compound heterozygous variants in ASXL3 causing BRPS-like features with primary IGF1 deficiency proposed the additively or synergistically effect and the complex interaction network of ASXL3 [32]. To date, there are three loss-of-function mutations (p.R322*, p.S887Ffs*2, p.P2037Hfs*43) in the ASXL3 gene within the ExAC (Exome Aggregation Consortium) dataset. These mutations are identified in phenotypically normal individuals and may be presumably explained by escaping from nonsense-mediated RNA decay due to their location. In addition, these mutations probably occurred post-zygotically or late in embryogenesis which is supported by some extent that somatic mutations occur in ASXL3 in cancers.
In conclusion, our study reports a novel heterozygous nonsense variant in a Chinese patient which expands the mutation spectrum in ASXL3 and clinical features of BRPS. Insights into the genetic etiology of BRPS are dependent on the causative gene study and further functional research. More case reports may help to elucidate the function of ASXL3 that may be critical to understand the etiology of the disease and facilitate genetic counselling and future prenatal testing.